| Abstract | In a phase III study of lansoprazole treatment, patients with healed or unhealed erosive esophagitis entered a titrated open-label treatment period and received lansoprazole for <or=6 years to assess long-term maintenance therapy. Doses were adjusted depending on symptom response. Endoscopy was performed yearly. One hundred ninety-five subjects received lansoprazole for <1 to 72 months; most received daily doses of <or=30 mg. Lansoprazole maintained erosive esophagitis remission in 75% of subjects receiving treatment for <or=72 months, with 39 subjects experiencing 50 recurrences. Most subjects (94-95%) had no or mild symptoms of day or night heartburn at study end, and 77% were asymptomatic at first erosive esophagitis recurrence. The most common treatment-related adverse events included diarrhea (10%), headache (8%), and abdominal pain (6%), and were mild or moderate in severity. Long-term lansoprazole is effective and well tolerated when used to maintain erosive esophagitis remission for <or=6 years. |
| Authors | Thomas O Kovacs, James W Freston, Marian M Haber, Barbara Hunt, Stuart Atkinson, David A Peura
(Affiliation: VA Greater Los Angeles Healthcare System, CURE Digestive Diseases Research Center, Los Angeles, CA 90073, USA. TKovacs at mednet.ucla.edu)
|
| Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 54
Issue 8
Pg. 1693-701
(Aug 2009)
ISSN: 1573-2568 [Electronic] United States |
| PMID | 19267194
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Proton Pump Inhibitors
- lansoprazole
|
| Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
(adverse effects, therapeutic use)
- Abdominal Pain
(chemically induced)
- Adult
- Aged
- Aged, 80 and over
- Diarrhea
(chemically induced)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Tolerance
- Esophagitis, Peptic
(prevention & control)
- Female
- Headache
(chemically induced)
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Proton Pump Inhibitors
(adverse effects, therapeutic use)
- Recurrence
(prevention & control)
- Treatment Outcome
|
